Article Text

Download PDFPDF
Clinical update
  1. Lewis Haddow1,
  2. Sophie Herbert2
  1. 1Centre for Sexual Health & HIV Research, Research Department of Infection and Population Health, University College London, London, UK
  2. 2Department of Genitourinary Medicine, Derby Hospitals NHS Foundation Trust, Derby, UK
  1. Correspondence to Dr Lewis Haddow, Research Department of Infection and Population Health, Centre for Sexual Health & HIV Research, University College London, London WC1E 6JB, UK; lewis.haddow{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Since October, clinical research teams around the UK have been busy prescribing Truvada as HIV pre-exposure prophylaxis (PrEP) for participants in the PROUD study who were originally randomised to defer at the time of enrolment. At the time of writing, we have a press release reporting that PrEP is highly protective against HIV: protective enough to amend the protocol and offer PrEP immediately to all participants.1 By the time this round-up is published, it is likely that the interim results will be in the public domain. The trial was originally set up as a pilot with the assumption that the sample size of 545 might be too small to see a difference between arms. That the trial is being amended early means one or both of two things: that the participants were at higher risk of HIV than anticipated and that the group randomised to immediate PrEP were more adherent, perhaps more committed, than participants in previous PrEP trials.

It now seems that the question is not if but when PrEP will reach our formularies. …

View Full Text


  • Provenance and peer review Commissioned; internally peer reviewed.